Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Glenwood GmbH, Pharmazeutische Erzeugnisse, Arabellastrasse 17, 81925 Munich, Germany
Catapres Tablets 100 micrograms.
| Pharmaceutical Form |
|---|
|
Tablet. White, round, flat, bevel-edged tablets impressed with the motif 01C / 01C on one side. |
Each tablet contains clonidine hydrochloride 100 micrograms.
For excipients see 6.1.
| Active Ingredient |
|---|
|
Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Opaque PVC 250 μm/PVDC 40g/m² blisters with aluminium lidding foil 20 μm containing 50, 84, 100 or 250 tablets. Not all pack sizes are marketed.
Glenwood GmbH, Pharmazeutische Erzeugnisse, Arabellastrasse 17, 81925 Munich, Germany
PA2256/003/001
Date of first authorisation: 1st April 1979
Date of last renewal: 1st November 2005
| Drug | Countries | |
|---|---|---|
| CATAPRES | Australia, Ireland, Japan, Malta, New Zealand, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.